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Abstract
Background: Understanding how comorbidity measures contribute to patient mortality is essential both to
describe patient health status and to adjust for risks and potential confounding. The Charlson and Elixhauser
comorbidity indices are well-established for risk adjustment and mortality prediction. Still, a different set of
comorbidity weights might improve the prediction of in-hospital mortality. The present study, therefore, aimed to
derive a set of new Swiss Elixhauser comorbidity weightings, to validate and compare them against those of the
Charlson and Elixhauser-based van Walraven weights in an adult in-patient population-based cohort of general
hospitals.
Methods: Retrospective analysis was conducted with routine data of 102 Swiss general hospitals (2012–2017) for
6.09 million inpatient cases. To derive the Swiss weightings for the Elixhauser comorbidity index, we randomly
halved the inpatient data and validated the results of part 1 alongside the established weighting systems in part 2,
to predict in-hospital mortality. Charlson and van Walraven weights were applied to Charlson and Elixhauser
comorbidity indices. Derivation and validation of weightings were conducted with generalized additive models
adjusted for age, gender and hospital types.
Results: Overall, the Elixhauser indices, c-statistic with Swiss weights (0.867, 95% CI, 0.865–0.868) and van Walraven’s
weights (0.863, 95% CI, 0.862–0.864) had substantial advantage over Charlson’s weights (0.850, 95% CI, 0.849–0.851)
and in the derivation and validation groups. The net reclassification improvement of new Swiss weights improved
the predictive performance by 1.6% on the Elixhauser-van Walraven and 4.9% on the Charlson weights.
Conclusions: All weightings confirmed previous results with the national dataset. The new Swiss weightings model
improved slightly the prediction of in-hospital mortality in Swiss hospitals. The newly derive weights support
patient population-based analysis of in-hospital mortality and seek country or specific cohort-based weightings.
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Background
Critical health outcomes such as mortality often require
effective risk adjustment based on patient characteristics
to predict in-hospital mortality. This is also true for co-
morbidities [1, 2], which function as major predictors of
mortality [3]. Over one-third of hospitalized patients
have at least one comorbidity; two-thirds of those over
65 [2, 4] and three-quarters of those over 85 have at
least two [5]. In addition to mortality, comorbidities are
associated with lower health-related quality of life, in-
creased disability and higher utilization of both health
care services and prescribed medications [6–8].
Data on comorbidities are valuable both for compari-
son between patient populations and for risk adjustment
regarding associated outcomes, especially mortality [9].
Two of the best-known measures are the Charlson Co-
morbidity Index and the Elixhauser Comorbidity Index
[10, 11]. When the Charlson Comorbidity Index was de-
veloped in 1987 it included 19 chronic conditions to
predict one-year mortality, but has since been shortened
to 17. The Elixhauser Comorbidity Index, which was de-
veloped in 1998, works on a similar system but includes
30 – or, for some variants, 31 – comorbidities. In
addition to in-hospital mortality, it is also used to pre-
dict the length of stay, adverse events and hospital dis-
charges [12, 13]. Despite this additional versatility
(covering acute and chronic conditions) and strong evi-
dence that the Elixhauser Comorbidity Index is statisti-
cally superior to the Charlson Comorbidity Index [13,
14], the Charlson Comorbidity Index continues to be
used. Because of the fewer chronic conditions [15–17]
and comparative ease of use in routine situations where
time is limited.
Both indices work either via simple (unweighted) sum
scores or as weighted scores assigning a risk weight to
each comorbidity [6, 18, 19]. A weighted sum score/
summary measure provides an attractive advantage over
plain dummy variables [20, 21], as it reduces the overfit-
ting risk of more parameters, unjustifiable in small data-
sets [22] and limits computational requirements in large
ones [21]. Additionally, evidence indicates that a
weighted variable reduces type I errors compared to
dummy variables while addressing multicollinearity con-
cerns in regression analysis and organizing multiple
highly correlated variables into more meaningful infor-
mation [21, 23]. The weight assigned to each comorbid-
ity reflects a higher, lower or neutral risk of mortality
[24]. Practically, mortality risk scores can help to identify
high-risk cases for special management and to assess
provider services whose patients perform better or worse
than expected from the summary measure of the mor-
bidity burden.
To add to the value of early versions of the Elixhauser
comorbidities, van Walraven et al. [25] used roughly 13
years’ inpatient admission data from one Canadian hos-
pital (1996–2008) to develop a set of weights (VW
weights, i.e., the regression coefficient divided by the co-
efficient in the model with the smallest absolute value)
for the 30 Elixhauser comorbidities associated with in-
hospital mortality. Using the backward selection and an
alpha inclusion criterion of 0.05 to identify independ-
ently associated comorbidities, van Walraven identified
21 comorbidities significantly associated with mortality.
A VW weight was assigned to each of the 21 Elixhauser
comorbidities. Ultimately, VW weights ranged from − 7
to 12, with a weight of 0 assigned to the 9 non-
significant comorbidities.
Since then, primarily in North America, studies have
used VW weights to predict in-hospital mortality, espe-
cially in clearly defined patient groups such as surgical,
orthopaedic, or cancer patients and those in single hos-
pitals or intensive care unit (ICU) [12, 13, 21, 25, 26].
Moreover, the comorbidity weighting system might dif-
fer between all hospitalization and a restricted cohort;
mortality and other outcomes; and between the coun-
tries [27]. Few studies have applied comorbidity adjust-
ments to national or regional inpatient datasets [21, 28].
Therefore, an analysis of a large heterogeneous patient
population from a national dataset (Switzerland) is justi-
fied both to provide an overview of Elixhauser comor-
bidities in a European sample and potentially to
optimize the comorbidity weights. In addition to increas-
ing the generalizability of these comorbidity weights, the
use of such a dataset, representing all hospital inpatient
cases (i.e., hospitalisation episodes) from a large, hetero-
geneous patient population, would allow a very accurate
comparison of weighting systems. Therefore, the aims of
our study were 1) to derive a new Swiss comorbidity
weighting on a national inpatient dataset to predict in-
hospital mortality; 2) to validate Charlson, Elixhauser-
van Walraven and new weights on a national inpatient
dataset; and 3) to compare the predictive performance of
in-hospital mortality of the three weighting systems.
Methods
Study design and population
This is a retrospective population-based analysis of 6
years’ data (2012–2017) from the Swiss national in-
patient dataset. Upon our application, subject to a data
protection contract (as stipulated by article 22 of the
Swiss Federal Act on Data Protection), the Swiss Federal
Statistics Office (FSO) provided anonymized data from
all Swiss hospital inpatient cases hospitalized between
2012 and 2017. This included not only general hospitals
but also special care (e.g., paediatric, gynaecological) fa-
cilities [29]. The FSO classifies general hospitals (Univer-
sity hospitals, Tertiary hospitals, and three Basic
hospitals) into five different levels, based on the number
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of cases treated per year and/or a special hospital score
assigned by Swiss Medical Association (“FMH-Kategor-
ien”). For this study, special care hospitals and children
were excluded because of the low levels of comorbidities
and the relatively low risk of dying in the hospital [25].
For data protection reasons, age was grouped in five-
year groups, and all inpatient cases below 20 years of age
were excluded. The flowchart for the final adult popula-
tion included 102 general hospitals (6,094,672 inpatient
cases) for the analysis is reported in supplementary Fig.
F1 (Additional file 1).
Dataset and classification of comorbidities indices
The dataset included patient characteristics including
sex, age, hospital types, primary and secondary diagnoses
based on International Classification of Diseases-10
(ICD-10) codes and hospital discharge information in-
cluding in-hospital mortality. As condition coding in
Switzerland is based on the ICD-10 German Modifica-
tion (ICD-10 GM), reported in supplementary Table S1
(Additional file 1), we used this to identify both Charlson
and Elixhauser comorbidities. Specifically, we used Quan
et al.’s ICD-10 codes [19] to determine each of the 17
Charlson and 31 Elixhauser comorbidities via the “Co-
morbidity” package in R [18]. This transforms ICD-10
codes into binary data the relevant comorbidities, their
(unweighted) sum scores, and their Charlson and VW-
weighted scores.
Descriptive analysis
The study population’s general characteristics (hospital
types, patient’s sex, and age groups) were reported in the
alive and mortality cohorts with percentages. The distri-
butions of Charlson and Elixhauser comorbidities, un-
weighted and weighted scores were computed as
percentages of index values of 0, 1–2, and ≥ 3 and < 0, 0,
1–4, and ≥ 5; and as the Charlson weight do not use
negative weightings, its weights were calculated for index
values of 0, 1–4, and ≥ 5. For each characteristic and co-
morbidities, standardized mean differences (SMD) be-
tween the alive and mortality cohort were computed
using “tableone” package in R. The SMD is identical to
Cohen’s D and provides an effect size estimate less sen-
sitive to the sample size than p values between the co-
horts. This is important in a dataset of the size used in
this study. An SMD of zero means there is no difference
in the characteristics (e.g., gender) between the alive and
mortality cohort. SMDs greater than 0.1 indicate poten-
tially relevant differences [30], i.e., showing unbalanced
covariates and might have an association with mortality.
Derivation of Swiss comorbidity weights
The study population was randomly split into a deriv-
ation (50%) and a validation (50%) group. The derivation
group was used to determine the adjusted association of
all 31 Elixhauser comorbidities with death, treating the
anonymous hospital identifier as a random effect [31].
Generalized additive regression models (GAM) can ac-
commodate many predictors including random effect,
able to handle large dataset easily and nonparametric in
nature [32]. We fitted GAM to compute the odds ratios
(OR) using the package “mgcv” [33] and R programming
language, version 3.5.2 [34]. We utilized GAM with ran-
dom effect components on the hospital level, as univer-
sity and small hospitals are different in size and services
in Switzerland. To identify Elixhauser comorbidities as-
sociated with in-hospital mortality, we retained variables
based on an alpha inclusion criterion of 0.01.
To derive the Swiss weightings from the regression
model’s parameter estimates, we used the method de-
scribed by Sullivan et al. [35]. Comorbidities not signifi-
cantly associated with mortality were assigned a weight
of zero. The number of (weighted) points assigned to
each comorbidity equalled its regression coefficient di-
vided by the coefficient in the model with the smallest
absolute value [14, 21, 25, 35] rounded to the nearest
whole number. Each person’s new Elixhauser comorbid-
ity weighting score was then calculated by summing up
all points of all their coded comorbidities.
Validation and comparison of weighted comorbidity
models
To validate and compare the performance of the three
comorbidity weighting systems, we first created four
multivariate in-hospital mortality prediction GAMs for
the derivation group. The first model, ‘base’, contained
no comorbidity data – only age group, sex, and hospital
types. The other three models used the same variables as
the base model, with the first, ‘Charlson’, using Charlson
weights, the second, ‘van Walraven’, using the Elixhauser
index with van Walraven weights, and the third, ‘Swiss
weights’, using our newly-developed weights. We then
validated all weights in validation groups by splitting the
validation group into six groups by year of discharge.
Altogether, 24 c statistics (including base models) were
computed to validate the Charlson, van Walraven, and
Swiss weights models in the validation sample. An add-
itional four models were created using all cases (combin-
ing derivation and validation groups) to evaluate the
performance of each model in the total patient
population.
We assessed the various comorbidity weightings ac-
cording to the model performance criteria. Discrimin-
ation, i.e., each model’s ability to distinguish patients
discharged alive from those who died in hospital, was
compared using the concordance (c) statistic. The c-
statistic quantified each model’s ability to assign high
probabilities of mortality to patients who died [36]. It’s
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possible values range from 0.50 to 1.0, with 0.50 indicat-
ing no ability to discriminate, values less than 0.70 are
considered poor, those between 0.70 and 0.80 accept-
able, and those of 0.80 or above excellent [37]. Using
bootstrap methods, we computed 95% confidence inter-
vals for each c-statistic. Additionally, the observed value
was also explored for each model from the predicted
values to observe the model performances in the highest
selected percentages (1, 2, 5 and 10%) in the derivation
sample. We also graphed receiver-operating characteris-
tic curves (ROC) for the visual presentation of the deriv-
ation group’s c statistics. We compared the base model
and existing comorbidity models with Swiss weight
model using net reclassification improvement (NRI) for
binary outcome [38–40] from the “nricens” package in R
[41] using the Swiss derivation sample and classification
cut-off value of 0.023 (mortality proportion of the total
study population). NRI measures the degree of improve-
ment in predicted inpatient mortality probabilities when
comorbidity weights are added to the base model [21,
42]. Higher NRI values indicate more accurate
reclassification.
Code validation and sensitivity analyses
We also evaluated the R comorbidity package’s code
handling accuracy in the Swiss setting. To do so we sam-
pled 100 cases and manually reviewed the Swiss ICD-10
codes of the raw data, checking whether the “comorbid-
ity” package had assigned each to the appropriate Charl-
son or Elixhauser comorbidity. We also performed
sensitivity analyses to explore Switzerland’s Major Diag-
nostic Categories’ (MDCs’) associations, which are based
on ICD-10 GM (one way of expressing the reason for
admission), if any, regarding the change in the predict-
ability of in-hospital mortality in combination with the
above models and to test whether the combined models’
patterns differed from those of uncombined ones. MDCs
are 24 mutually exclusive categories into which all pri-
mary diagnoses are assigned based on the Swiss




Overall, the adult inpatient population between 2012
and 2017 in all Swiss general hospitals (102) consisted of
6,094,672 cases. Among all hospitalized cases in our
study population mortality was 2.3%. The characteristics
of the adult inpatient cases are presented in Table 1. In-
patient cases had between 0 and 9 Charlson comorbidi-
ties (median 0, interquartile range (IQR): 0–1) and
between 0 and 16 Elixhauser comorbidities (median 1,
IQR: 0–2). The different categories of three comorbidity
weightings are presented in supplementary Table S2
(Additional file 1).
Prevalence of Charlson and Elixhauser comorbidity
indices
The most common Charlson comorbidity was any ma-
lignancy (including lymphoma and leukaemia, except
malignant neoplasm of the skin) in both cohorts, alive
(10.2%) and mortality (37.6%), yet with marked differ-
ences between the two cohorts (SMD: 0.680). The preva-
lence for each Charlson comorbidity in the total
population and the derivation is presented in supple-
mentary Table S3 (Additional file 1).
The most common Elixhauser comorbidities were un-
complicated hypertension (22.7%) in the alive cohort,
whereas in the mortality cohort, it was solid tumour
without metastasis (33.7%). However, the most pro-
nounced difference between both cohorts was observed
for metastatic cancer (4.0% vs. 26.5%; SMD: 0.657). The
prevalence for each Elixhauser comorbidity from the
total population and derivation group is presented in the
supplementary Table S4 (Additional file 1).
Derivation of Swiss weights
In the derivation group, two of the 31 Elixhauser comor-
bidities showed no association with hospital mortality
and were removed, leaving 29 in the final model with
random effect on the hospital level. Sixteen were associ-
ated with increased mortality risk, with the strongest as-
sociations coming from metastatic cancer (OR: 4.09,
95% CI: 3.98–4.21) and liver disease (OR: 3.83, 95% CI:
3.70–3.97). At the other end of the spectrum, 13 comor-
bidities were associated with a decreased risk of hospital
mortality. The strongest of these were deficiency an-
aemia (OR: 0.54, 95% CI: 0.51–0.56) and obesity (OR:
0.59, 95% CI: 0.56–0.63). The adjusted coefficients were
used to derive Swiss weights with a new maximum
weight of 17, for metastatic cancer, and a new minimum
of − 7, for deficiency anaemia (Table 2).
Validation and comparison of weighted comorbidity
models
All three comorbidity weighting systems (Charlson, Elix-
hauser van Walraven and Swiss) indicated higher in-
hospital mortality risk than the base model, showing the
conditional interpretation of weights for each of the
weighted models. Each model performed similarly across
all years in validation groups as in the derivation groups.
Overall, the c-statistic for the 6-year cohort were: 0.757
(95% CI: 0.755–0.759) for the base model, 0.850 (95%
CI: 0.849–0.851) for Charlson, 0.863 (95% CI: 0.862–
0.864) for VW Elixhauser and 0.867 (95% CI: 0.865–
0.868) with Swiss Elixhauser. These c-statistics were
similar in the development and validation cohorts. All
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differences and the rankings they established among
models were statistically significant. (Additional file 1,
Table S5). In comparison, the model with Swiss weights
discrimination was slightly better with some c-statistic
variability across the 6 years’ data.
Additionally, 1% highest predicted value, showed
the same order of the model’s performance from the
observed mortality (base: 10.7%, Charlson: 18.5%, VW
Elixhauser: 20.4%, Swiss Elixhauser: 20.9% (Table S6,
Additional file 1). As shown in receiver-operating
characteristic (ROC) curves (Fig. 1) the Swiss weights
model’s discrimination was better than the Charlson’s
or base model’s, and only slightly better than the van
Walraven’s. The NRI confirm this picture (Table 3).
Comparing the Swiss weights with VW weights
showed an NRI of 1.6% (95%-CI: 1.3–2.0) with differ-
ences in predicted probabilities of mortality (among
those who died) of 1.4% and differences in predicted
probabilities of alive (among those who lived) by
0.02%.
Finally, the sensitivity analysis using MDCs did not
offer any improvements in the models’ performance.
Table 1 General characteristics of the total study population
Parameters Alive cohort (%) Mortality cohort (%) SMD
aTotal population: N = 6,094,672 5,952,005 (97.7) 142,667 (2.3)
Females 3,280,823 (55.1) 63,912 (44.8) 0.208
Age groups 1.006
20–24 years 215,672 (3.6) 292 (0.2)
25–29 years 327,562 (5.5) 375 (0.3)
30–34 years 415,022 (7.0) 526 (0.4)
35–39 years 348,591 (5.9) 718 (0.5)
40–44 years 299,985 (5.0) 1368 (1.0)
45–49 years 350,899 (5.9) 2503 (1.8)
50–54 years 408,028 (6.9) 4312 (3.0)
55–59 years 430,721 (7.2) 6503 (4.6)
60–64 years 466,543 (7.8) 9068 (6.4)
65–69 years 528,374 (8.9) 13,322 (9.3)
70–74 years 554,612 (9.3) 16,899 (11.8)
75–79 years 535,543 (9.0) 19,888 (13.9)
80–84 years 509,225 (8.6) 24,853 (17.4)
85–89 years 365,924 (6.1) 24,042 (16.9)
90–94 years 161,236 (2.7) 14,156 (9.9)
95+ years 34,068 (0.6) 3842 (2.7)
Hospital types 0.157
University (level 1) 1,078,612 (18.1) 29,379 (20.6)
Tertiary care (level 2) 3,274,382 (55.0) 83,686 (58.7)
Basic care (level 3) 736,465 (12.4) 14,863 (10.4)
Basic care (level 4) 671,182 (11.3) 10,695 (7.5)
Basic care (level 5) 191,364 (3.2) 4044 (2.8)
Number of Charlson comorbidities 1.234
0 3,642,650 (61.2) 17,465 (12.2)
1–2 1,907,761 (32.1) 80,876 (56.7)
> = 3 401,594 (6.7) 44,326 (31.1)
Number of Elixhauser comorbidities 1.039
0 2,509,169 (42.2) 11,036 (7.7)
1–2 2,106,780 (35.4) 43,494 (30.5)
> = 3 1,336,056 (22.4) 88,137 (61.8)
Abbreviations: SMD standardized mean difference between alive and mortality cohort
aTotal population presented in row percentage
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Discussion
This study used a six-year dataset of a multi-million-
patient population to explore Charlson and Elixhauser
comorbidities with different weightings to predict in-
hospital mortality. We first derived a set of Swiss weight-
ings for the 31 Elixhauser comorbidities using the na-
tional inpatient dataset. The analysis confirmed
Charlson and Elixhauser comorbidities with van
Walraven’s weights performance for mortality predic-
tion, while the newly derived Swiss weightings slightly
improved the mortality prediction for the 31 Elixhauser
comorbidities.
Although, the optimized Swiss weightings performed
only slightly better than the Charlson and Elixhauser-
van Walraven sets they also supplied weights for eight
Elixhauser comorbidities (e.g. diabetes, hypertension,
Table 2 Prevalence, adjusted odds ratio and weights from the (new) Swiss derivation sample and the van Walraven (VW) derivation
sample [25]
Elixhauser comorbidities Alive cohort (%) Mortality cohort (%) SMD Adjusted odds ratio (95% CI) Weights
Swiss derivation sample VWa Swiss VWa Swiss
bDerivation group 2,975,887 (97.7) 71,449 (2.3)
Congestive heart failure 163,685 (5.5) 16,333 (22.9) 0.514 1.96 (1.85–2.07) 3.07 (3.00–3.14) 7 13
Cardiac arrhythmias 341,280 (11.5) 20,754 (29.0) 0.448 1.71 (1.62–1.80) 1.69 (1.66–1.73) 5 6
Valvular disease 117,450 (3.9) 6568 (9.2) 0.213 0.91 (0.82–0.99) 0.92 (0.89–0.95) -1 -1
Pulmonary circulation disorders 53,292 (1.8) 4813 (6.7) 0.247 1.48 (1.34–1.62) 1.62 (1.57–1.68) 4 6
Peripheral vascular disorders 141,051 (4.7) 6912 (9.7) 0.192 1.26 (1.17–1.36) 1.27 (1.24–1.31) 2 3
Hypertension (uncomplicated) 676,609 (22.7) 15,692 (22.0) 0.019 – 0.69 (0.68–0.70) 0 −4
Hypertension (complicated) 218,656 (7.3) 11,003 (15.4) 0.256 – 0.79 (0.77–0.81) 0 −3
Paralysis 61,546 (2.1) 5153 (7.2) 0.246 1.93 (1.75–2.12) 2.60 (2.52–2.69) 7 11
Other neurological disorders 120,045 (4.0) 8011 (11.2) 0.273 1.83 (1.70–1.96) 2.45 (2.39–2.52) 6 10
Chronic pulmonary disease 170,770 (5.7) 8269 (11.6) 0.209 1.36 (1.29–1.44) 1.31 (1.27–1.34) 3 3
Diabetes, uncomplicated 245,817 (8.3) 9059 (12.7) 0.145 – 1.09 (1.06–1.11) 0 1
Diabetes, complicated 66,161 (2.2) 2763 (3.9) 0.096 – 0.89 (0.86–0.93) 0 −1
Hypothyroidism 126,062 (4.2) 3454 (4.8) 0.029 – 0.76 (0.74–0.79) 0 −3
Renal failure 289,047 (9.7) 20,526 (28.7) 0.497 1.63 (1.54–1.73) 2.06 (2.02–2.11) 5 8
Liver disease 49,916 (1.7) 5822 (8.1) 0.303 2.97 (2.73–3.22) 3.83 (3.7–3.97) 11 16
Peptic ulcer disease, excluding bleeding 5808 (0.2) 258 (0.4) 0.032 – – 0 0
AIDS/HIV 2300 (0.1) 85 (0.1) 0.013 – – 0 0
Lymphoma 25,049 (0.8) 1759 (2.5) 0.127 2.55 (2.31–2.81) 2.19 (2.07–2.31) 9 9
Metastatic cancer 119,667 (4.0) 18,907 (26.5) 0.657 3.30 (3.10–3.52) 4.09 (3.98–4.21) 12 17
Solid tumour without metastasis 268,298 (9.0) 24,046 (33.7) 0.631 1.47 (1.39–1.56) 2.36 (2.3–2.42) 4 10
Rheumatoid arthritis/collagen vascular diseases 47,305 (1.6) 1254 (1.8) 0.013 – 0.91 (0.86–0.97) 0 −1
Coagulopathy 90,551 (3.0) 9528 (13.3) 0.382 1.30 (1.22–1.40) 2.12 (2.07–2.18) 3 9
Obesity 68,155 (2.3) 1011 (1.4) 0.065 0.64 (0.53–0.77) 0.59 (0.56–0.63) −4 −6
Weight loss 98,545 (3.3) 9527 (13.3) 0.369 1.85 (1.67–2.04) 1.67 (1.63–1.71) 6 6
Fluid and electrolyte disorders 257,618 (8.7) 17,440 (24.4) 0.434 1.61 (1.53–1.69) 1.58 (1.55–1.61) 5 5
Blood loss anaemia 19,759 (0.7) 685 (1.0) 0.033 0.81 (0.70–0.93) 0.66 (0.60–0.71) −2 −5
Deficiency anaemia 72,290 (2.4) 1886 (2.6) 0.013 0.80 (0.71–0.90) 0.54 (0.51–0.56) −2 −7
Alcohol abuse 96,708 (3.2) 3086 (4.3) 0.056 – 0.75 (0.72–0.78) 0 −3
Drug abuse 38,044 (1.3) 583 (0.8) 0.045 0.50 (0.42–0.60) 0.67 (0.61–0.73) −7 −5
Psychoses 29,598 (1.0) 404 (0.6) 0.049 – 0.72 (0.65–0.79) 0 −4
Depression 173,898 (5.8) 3715 (5.2) 0.028 0.73 (0.67–0.80) 0.73 (0.70–0.75) −3 −3
The total cohort percentages can exceed 100%, as each admission contributes to one or more comorbidities. Swiss weights are calculated by dividing the
coefficient of each comorbidity by the coefficient in the model with the smallest absolute value (which is ‘diabetes uncomplicated’ with a coefficient of 0.084) and
rounding to the nearest whole number
Abbreviations: SMD standardized mean difference between alive and mortality cohort, VWa van Walraven, `–` excluded in the final model, bRow percentage
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and psychosis) eliminated by van Walraven et al. (2009)
[25]. Of the risk-associated comorbidities retained in
both the van Walraven and the Swiss weights, several
comorbidities showed similar results, e.g., the highest
odds ratios to metastatic cancer and liver disease. And
regarding the comorbidities with negative associations,
only small differences were observed between the van
Walraven and Swiss weights (e.g., hypothyroidism or
obesity were likely to be healthier).
From an epidemiological perspective, overall
hospitalization mortality was only 2.3%, but in-hospital
mortality is higher in patients with chronic diseases.
Chronic diseases such as cancer, heart and liver diseases
increase the risk of dying in hospitals, while certain
other less severe diseases, (e.g., hypertension, anaemia
and hypothyroidism) have a lower risk. This might be
due to the relatively higher frequency of less severe dis-
eases and some reported along with other acute condi-
tions for the same patients. Furthermore, the
interpretation of the algebraic sign of a single coefficient
from such a joint model is mainly for the derivation of
the weights, especially negative weights do not support
the survival of the patients. These results are in line with
those of Zellweger et al.’s [44] study using the Swiss na-
tional death registry of hospital inpatient data from 2010
to 2012. Furthermore, van Walraven et al.’s [25] study
based on a single Canadian hospital’s records and
Thompson et al., [21] using Maryland State inpatient
data, showed similar results. These relations could
insight the global burden of in-hospital mortality is due
to rising chronic diseases.
The existing weighting systems [11, 13, 21, 25] repre-
sent data from a specific geographical region, patient
group, or even limited numbers of hospitals or settings,
matching the generalizability of these weighting systems
remained difficult. As this study addresses such issues,
with a large dataset representing the Swiss inpatient
population, it provides Swiss comorbidity adjustments
for the prediction of mortality or other health outcomes.
The c statistics reported in our study (weighted models)
are around 10% higher than those reported in van Wal-
raven’s study [25]. Several reasons might explain this in-
crease: the GAM modelling approach (with binomial
family) including random effects contributing around 2%
improvement in c statistic without random effect, the
Fig. 1 Receiver-operating characteristic (ROC) curves for generalized
additive models predicting in-hospital mortality. Base model (AUC
0.757): age group, sex, hospital types; Charlson weights model (AUC
0.850): base and Charlson weights; VW weights model (AUC 0.863):
base and Elixhauser/ van Walraven weights; Swiss weights model
(AUC 0.867): base and Elixhauser/ Swiss weights. Straight diagonal
line in the middle showing null model (AUC 0.500)
Table 3 Comparison of Swiss weights model with Base, Charlson and VW weights models based on the Net Reclassification
Improvement (NRI)
Derivation group










Swiss weights vs. Base
model
0.355 (0.352–0.357) 0.448 (0.445–0.450) 0.074 (0.074–0.074) 0.134 (0.133–0.136) 0.115 (0.115–0.116)
Swiss weights vs.
Charlson weights model
0.049 (0.044–0.052) 0.297 (0.294–0.299) 0.058 (0.058–0.059) 0.251 (0.250–0.253) 0.062 (0.061–0.062)
Swiss weights vs. VW
weights model
0.016 (0.013–0.020) 0.157 (0.155–0.159) 0.021 (0.021–0.022) 0.143 (0.140–0.145) 0.023 (0.023–0.024)
Abbreviations: NRI Net Reclassification Improvement with classification cut-off 0.023, CI confidence interval
Pr (Up, Down) | (Case, Ctrl) represents the proportion of patients whose predicted probabilities increased or decreased for in-hospital mortality and alive
cohorts respectively
NRI = (Pr (Up|Case) - Pr (Down|Case)) + (Pr (Down|Ctrl) - Pr (Up|Ctrl))
Base model: age group, sex, hospital types
Charlson weights model: base and Charlson weights
VW weights model: base and Elixhauser/ van Walraven weights
Swiss weights model: base and Elixhauser/ Swiss weights
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study cohort and hospital types included might raise the
base model and largely the conditional interpretation of
weightings effect raised c statistic of weighted models.
With the new eight derivations, the additional eight sig-
nificant variables might have played a role too. However,
a slightly improved performance of the Swiss weights
system suggests that it might be worthwhile to derive
country- or region-specific comorbidity weights from
representative patient populations.
C-statistics and ROCs are widely used to assess pre-
dictive performance. Nonetheless, one downside of com-
paring c-statistic and ROCs is that differences between
c-statistics are often small, [45] as it was the case when
we compared our new weights and van Walraven’s. Over
the past decade, it has become common to use NRIs to
compare different models’ performance, even though it
might differ with the cut-offs taken for analysis [39, 46].
In our study, taking the same cut-offs for all models,
NRI calculations confirmed the three weighting systems’
rankings i.e., Swiss, van Walraven and Charlson weights.
The primary strength of this study was the large sam-
ple size and the heterogeneity of the Swiss inpatient
population across all general hospitals over 6 years,
which made it representative of the entire country. To
our knowledge, this study is the first to derive and valid-
ate Elixhauser weightings in Swiss hospital inpatient
data. We used standard regression methodology for large
datasets, including random effects at the hospital level,
and internally validated our models. We also used ac-
cepted methods to modify our adjusted model into a
Swiss weightings system that re-includes the association
of several comorbidities (e.g., diabetes, hypertension,
Psychoses) formerly excluded from the Elixhauser index
in the VW study [35]. Despite differences in individual
comorbidities’ prevalence and weightings, Charlson,
Elixhauser/VW, and the Swiss weights performed well
across the derivation, validation, and all-cases groups.
We also used NRIs, allowing a robust comparison of
model performance. Finally, the methods we applied
were explicit and can be replicated by other researchers,
who can adjust or control for patient comorbidity via
their hospital and national databases. Moreover, the
managerial utility could be done using this method by
identifying high-risk patients for safe care and by evalu-
ating hospitals performance based on the patient’s
outcome.
Our study also has certain notable limitations. We de-
rived our weights using statistical criteria, while clinical
knowledge might be needed to determine each comor-
bidity’s value. Since we used codes assigned in routine
data, the capture of the comorbidities could be influ-
enced by other factors, such as physician and nurse
documentation, code assignment accuracy, and the pos-
sibility that capture of comorbidities is biased towards
those for which the Swiss DRG / MDC pays more [43,
47]. The negative coefficients/weights might be artefacts,
as they are computed using routine data and coding of
these is influenced by the main diagnose (e.g., deficiency
anaemia, diabetes or hypertension are far more likely to
be recorded when a patient had few other serious or
acute problems). The direction of the coefficients is also
driven by the joint adjusted model, which makes the in-
terpretation of a single coefficient not meaningful. More-
over, some researchers believe current comorbidity
indices are not suitable for use as predictors of patient-
centred outcomes like rehabilitation, readmission, fee-
for-services while weightings might differ in restricted
cohorts, other outcomes and countries [27]. Addition-
ally, Swiss data protection regulations prevented us from
obtaining the inpatients’ exact age, we could not differ-
entiate children exactly under 18 years and could not
specify each year. This also might have influenced the
predictive accuracy of the tested models.
Conclusions
We found that Elixhauser/van Walraven weightings per-
formed well in a large Swiss dataset and could derive
Swiss weightings with statistically significant, yet with a
small improvement in mortality prediction. Although
the Swiss weightings showed slightly improved mortality
predictions, we confirmed the validity of the Elixhauser/
van Walraven weightings. The results provide evidence
that Elixhauser/van Walraven weightings continue to be
the preferred choice for weighting. In the Swiss context
and possibly in countries with ICD-10 GM (German
Modification) the derived weights are an option and to
identify high-risk patients for safe care/treatment. Given
access to similar data, researchers could use the methods
described here to validate existing weightings such as
van Walraven or derive their own country- or region-
specific morbidity weights, although improvements
might be small.
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